

Greg Mouchka
iFyber, LLC
607.229.5322
greg@ifyber.com



iFyber awarded \$4.2MM from DoD to develop novel antimicrobial wound dressings

iFyber to develop standard issue and field administered antimicrobial dressings to treat thousands of wounded warriors annually

October 21, 2020 (Ithaca, NY): iFyber announced that it has entered into multiple agreements with the Department of Defense (DoD), which will provide funds for the development of two distinct types of antimicrobial dressings designed for different use scenarios. The first effort will focus on developing a cotton-based standard issue antimicrobial field dressing that utilizes iFyber's extensive experience working with copper coatings and builds on iFyber's previous work with DoD in this area. The second will produce a field-administered, antimicrobial burn dressing that incorporates copper along with hydrogels to create a moist, microbe-free wound site, which is critical for healing.

"Since the inception of iFyber, we have believed that copper is a valuable tool in the battle against microbes," said Greg Mouchka, president of iFyber. Mouchka further shared that "the warfighter operates in a uniquely challenging environment, where the frequency, diversity and severity of wounds are unlike those in any other profession. We have learned a great deal over the past 12 years about the effectiveness of copper as an antimicrobial. The combination of copper together with the matrix in which it is delivered is critical for ensuring optimal outcomes across different applications."

The field dressing project is a \$3.2 million effort funded by the Congressionally Directed Medical Research Programs (CDMRP) Joint Program Committee-2/Military Infectious Diseases Research Program (JPC-2/MIDRP). The burn dressing project is a Small Business Innovation Research (SBIR) Direct to Phase II grant for \$1 million. These awards will allow iFyber to develop and commercialize a new class of antimicrobial dressings, which are based upon the Company's past copper research efforts.

"We're appreciative of the DoD's recognition of our past R&D efforts and are extremely excited to work with them on the development of copper-based, antimicrobial dressings that meet their specific requirements. Wounded warfighters need a standard issue solution that, once applied, can prevent microbes from colonizing the wound for the period of time necessary to reach a field hospital," said Aaron Strickland, VP of R&D and iFyber co-founder. "iFyber is well-positioned with our team of scientists and regulatory professionals to successfully bring these innovative devices to the market."

About iFyber: iFyber is a preclinical contract research organization that offers custom research and development services to companies that operate at the interface of chemistry, biology, and materials science. iFyber has additionally sponsored in-house R&D activities that have resulted in commercialization partnerships with medical device companies. iFyber is unique - we provide clients direct access to top scientists that can creatively solve problems and propose application-specific

models that best reflect the products real-world intended use. iFyber capability also extends to developing novel technology platforms for commercialization partners. Whether it is designing highly customized new technology efficacy testing or creatively solving any unexpected challenges that arise during validation testing and full-scale manufacturing, our value is in our ability to work quickly and collaboratively with our clients. In contrast to primarily offering standardized testing, we provide custom solutions to complex problems across numerous different areas of expertise.

Disclosures: This work is supported by the US Army Medical Research and Development Command (USAMRDC)/US Army Medical Materiel Development Agency (USAMMDA) under Contract No. W81XWH-20-C-0107 and by the Office of the Assistant Secretary of Defense for Health Affairs, through the U.S. Army Medical Research Acquisition Activity (USAMRAA) under Award No. W81XWH-20-1-0915. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.

###